Marlise R. Luskin
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Marlise R. Luskin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:22 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07227584 · ALL Backbone in AYAsDana-Farber Cancer Institute · recruiting · Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL)
- Ph2NCT05303792 · Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic LeukemiaAlliance for Clinical Trials in Oncology · active not recruiting · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma · study chair
- Ph1NCT05016947 · Venetoclax Plus Inotuzumab for B-ALLDana-Farber Cancer Institute · active not recruiting · B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL
- Ph1NCT03595917 · ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLMarlise Luskin, MD · recruiting · B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT05303792
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:22 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.Blood Cancer Discov · 2023128 citationsRCR 11.1
- Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.Blood · 2016112 citationsRCR 3.5
- Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.Blood Adv · 202449 citationsRCR 6.1
- Exploring the Feasibility of a Mindfulness-Music Therapy Intervention to Improve Anxiety and Stress in Adolescents and Young Adults with Cancer.J Pain Symptom Manage · 202232 citationsRCR 3.1
- Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.Blood · 202530 citationsRCR 7.7
- Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia.Blood Adv · 202530 citationsRCR 6.0
- Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.Lancet Haematol · 202027 citationsRCR 1.0
- Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trial.Cancer · 202319 citationsRCR 2.8
- Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia.Haematologica · 202414 citationsRCR 1.8
- 2 citationsRCR 0.4